{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=49",
    "query": {
      "condition": "Metastasis, Neoplasm",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 10748,
    "total_pages": 1075,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T21:21:32.923Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02089334",
      "title": "Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "RX-0201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rexahn Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-08",
      "completion_date": "2018-05-17",
      "has_results": true,
      "last_update_posted_date": "2020-06-30",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Duarte, California • Albuquerque, New Mexico + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02089334"
    },
    {
      "nct_id": "NCT07635524",
      "title": "A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cu-NU101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoag Memorial Hospital Presbyterian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 34,
      "start_date": "2026-08-01",
      "completion_date": "2028-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • St Louis, Missouri",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07635524"
    },
    {
      "nct_id": "NCT01401959",
      "title": "Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 127,
      "start_date": "2011-09-23",
      "completion_date": "2017-04-03",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 18,
      "location_summary": "Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01401959"
    },
    {
      "nct_id": "NCT02068079",
      "title": "A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vemurafenib and Trientine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-04",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02068079"
    },
    {
      "nct_id": "NCT00076388",
      "title": "Iressa Versus Docetaxel (Taxotere)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gefitinib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1440,
      "start_date": "2004-02",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2011-05-13",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076388"
    },
    {
      "nct_id": "NCT02855788",
      "title": "Metronomic Chemotherapy in Advanced Gastric Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Gastric Cancer",
        "Locally Advanced Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Huashan Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2015-05",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02855788"
    },
    {
      "nct_id": "NCT05764395",
      "title": "Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma",
        "Refractory Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Rigosertib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-05-09",
      "completion_date": "2026-03-13",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05764395"
    },
    {
      "nct_id": "NCT07450157",
      "title": "A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 6448,
      "start_date": "2023-06-23",
      "completion_date": "2025-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07450157"
    },
    {
      "nct_id": "NCT07287995",
      "title": "A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Malignant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASP2998",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 428,
      "start_date": "2026-02-05",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 5,
      "location_summary": "Celebration, Florida • Hackensack, New Jersey • New Hyde Park, New York + 2 more",
      "locations": [
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07287995"
    },
    {
      "nct_id": "NCT03473639",
      "title": "A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2019-01-29",
      "completion_date": "2022-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-01",
      "last_synced_at": "2026-10-27T21:21:32.923Z",
      "location_count": 2,
      "location_summary": "Rochester, New York • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473639"
    }
  ]
}